Advanced search
Publication Cover
Baylor University Medical Center Proceedings
The peer-reviewed journal of Baylor Scott & White Health
Volume 37, 2024 - Issue 1
Submit an article Journal homepage
75
Views
1
CrossRef citations to date
0
Altmetric
Original Research: Oncology

Independent predictors of mortality and 5-year trends in mortality and resource utilization in hospitalized patients with diffuse large B cell lymphoma

Zubair Hassan Bodlaa University of Central Florida College of Medicine, Graduate Medical Education, Orlando, Florida, USA;b HCA Florida North Florida Hospital, Internal Medicine Residency Program, Gainesville, Florida, USAORCID Iconhttps://orcid.org/0000-0003-1203-2766
, MDORCID Icon,
Mariam Hashmib HCA Florida North Florida Hospital, Internal Medicine Residency Program, Gainesville, Florida, USACorrespondence[email protected]
ORCID Iconhttps://orcid.org/0009-0003-0955-4640
, MDORCID Icon,
Fatima Niazc King Edward Medical University, Lahore, Punjab, Pakistan;d Mayo Hospital, Lahore, Punjab, PakistanORCID Iconhttps://orcid.org/0009-0008-1773-6811
, MDORCID Icon,
Umer Farooqe Rochester Regional Health, Rochester, New York, USAORCID Iconhttps://orcid.org/0000-0001-8272-0172
, MDORCID Icon,
Farhan Khalidf Monmouth Medical Center, Long Branch, New Jersey, USA
, MD,
Muhammad Junaid Tariqg Roswell Park Comprehensive Cancer Center, Buffalo, New York, USA
, MD,
Muhammad Jahanzeb Khalilh University of Alabama, Montgomery, Alabama, USAORCID Iconhttps://orcid.org/0009-0003-9573-3126
ORCID Icon,
Victoria S. Browni Florida Cancer Specialists and Research Institute, Gainesville, Florida, USA
, MD &
Christopher L. Braya University of Central Florida College of Medicine, Graduate Medical Education, Orlando, Florida, USA;b HCA Florida North Florida Hospital, Internal Medicine Residency Program, Gainesville, Florida, USA
, MD, PhD show all
Pages 16-24 | Received 19 Aug 2023, Accepted 24 Sep 2023, Published online: 23 Oct 2023

  • Li Y, Wang Y, Wang Z, Yi D, Ma S. Racial differences in three major NHL subtypes: descriptive epidemiology. Cancer Epidemiol. 2015;39(1):8–13. doi:10.1016/j.canep.2014.12.001.
  • Shi Y, Han Y, Yang J, et al. Clinical features and outcomes of diffuse large B-cell lymphoma based on nodal or extranodal primary sites of origin: analysis of 1,085 WHO classified cases in a single institution in China. Chin J Cancer Res. 2019;31(1):152–161. doi:10.21147/j.issn.1000-9604.2019.01.10.
  • Cabanillas F, Shah B. Advances in diagnosis and management of diffuse large B-cell lymphoma. Clin Lymphoma Myeloma Leuk. 2017;17(12):783–796. doi:10.1016/j.clml.2017.10.007.
  • Lamy T, Damaj G, Soubeyran P, et al. R-CHOP 14 with or without radiotherapy in nonbulky limited-stage diffuse large B-cell lymphoma. Blood. 2018;131(2):174–181. doi:10.1182/blood-2017-07-793984.
  • Poeschel V, Held G, Ziepert M, et al. Four versus six cycles of CHOP chemotherapy in combination with six applications of rituximab in patients with aggressive B-cell lymphoma with favourable prognosis (FLYER): a randomised, phase 3, non-inferiority trial. Lancet. 2019;394(10216):2271–2281. doi:10.1016/S0140-6736(19)33008-9.
  • Larouche J-F, Berger F, Chassagne-Clément C, et al. Lymphoma recurrence 5 years or later following diffuse large B-cell lymphoma: clinical characteristics and outcome. J Clin Oncol. 2010;28(12):2094–2100. doi:10.1200/JCO.2009.24.5860.
  • Sehn LH, Berry B, Chhanabhai M, et al. The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP. Blood. 2007;109(5):1857–1861. doi:10.1182/blood-2006-08-038257.
  • Ziepert M, Hasenclever D, Kuhnt E, et al. Standard International Prognostic Index remains a valid predictor of outcome for patients with aggressive CD20+ B-cell lymphoma in the rituximab era. J Clin Oncol. 2010;28(14):2373–2380. doi:10.1200/JCO.2009.26.2493.
  • NIS Database. Documentation. https://hcup-us.ahrq.gov/db/nation/nis/nisdbdocumentation.jsp. Accessed July 18, 2023.
  • Agency for Healthcare Research and Quality. Healthcare Cost and Utilization Project. https://www.ahrq.gov/data/hcup/index.html. Accessed July 15, 2023.
  • Charlson ME, Carrozzino D, Guidi J, Patierno C. Charlson Comorbidity Index: a critical review of clinimetric properties. Psychother Psychosom. 2022;91(1):8–35. doi:10.1159/000521288.
  • US Bureau of Labor Statistics. CPI inflation calculator. https://data.bls.gov/cgi-bin/cpicalc.pl. Accessed April 5, 2023.
  • Bodla ZH, Hashmi M, Niaz F, et al. Timing matters: an analysis of the relationship between red cell transfusion timing and hospitalization outcomes in sickle cell crisis patients using the National Inpatient Sample database. Ann Hematol. 2023;102(7):1669–1676. doi:10.1007/s00277-023-05275-6.
  • Shenoy PJ, Malik N, Nooka A, et al. Racial differences in the presentation and outcomes of diffuse large B-cell lymphoma in the United States. Cancer. 2011;117(11):2530–2540. doi:10.1002/cncr.25765.
  • Morton LM, Wang SS, Devesa SS, Hartge P, Weisenburger DD, Linet MS. Lymphoma incidence patterns by WHO subtype in the United States, 1992-2001. Blood. 2006;107(1):265–276. doi:10.1182/blood-2005-06-2508.
  • Shirley MH, Sayeed S, Barnes I, Finlayson A, Ali R. Incidence of haematological malignancies by ethnic group in England, 2001–7. Br J Haematol. 2013;163(4):465–477. doi:10.1111/bjh.12562.
  • Smith A, Howell D, Patmore R, Jack A, Roman E. Incidence of haematological malignancy by sub-type: a report from the Haematological Malignancy Research Network. Br J Cancer. 2011;105(11):1684–1692. doi:10.1038/bjc.2011.450.
  • Kumar AJ, Henzer T, Rodday AM, Parsons SK. Longer length of stay and no chemotherapy is associated with greater likelihood of death during hospitalization in patients with diffuse large B-cell lymphoma: an analysis from the National Inpatient Sample (NIS). Blood. 2017;130:2121. doi:10.1182/blood.V130.Suppl_1.2121.2121.
  • Ruppert AS, Dixon JG, Salles G, et al. International prognostic indices in diffuse large B-cell lymphoma: a comparison of IPI, R-IPI, and NCCN-IPI. Blood. 2020;135(23):2041–2048. doi:10.1182/blood.2019002729.
  • Warnnissorn N, Kanitsap N, Niparuck P, et al. External validation and comparison of IPI, R-IPI, and NCCN-IPI in diffuse large B-cell lymphoma patients treated with R-CHOP to predict 2-year progression-free survival. Hematology. 2022;27(1):1237–1245. doi:10.1080/16078454.2022.2147916.
  • Epperla N, Vaughn JL, Othus M, Hallack A, Costa LJ. Recent survival trends in diffuse large B-cell lymphoma—have we made any progress beyond rituximab? Cancer Med. 2020;9(15):5519–5525. doi:10.1002/cam4.3237.
  • Kumar AJ, Henzer T, Rodday AM, Parsons SK. Chemotherapy is administered to a minority of hospitalized patients with diffuse large B-cell lymphoma and is associated with less likelihood of death during hospitalization. Cancer Epidemiol. 2018;53:137–140. doi:10.1016/j.canep.2018.01.017.
  • Deenadayalan V, Olafimihan A, Ganesan V, Kumi D, Zia M. Impact of protein-energy malnutrition on outcomes of patients with diffuse large B cell lymphoma admitted for inpatient chemotherapy. Proc (Bayl Univ Med Cent). 2023;36(4):439–442. doi:10.1080/08998280.2023.2204285.
  • Durani U, Shah ND, Go RS. In-hospital outcomes of tumor lysis syndrome: a population-based study using the National Inpatient Sample. Oncologist. 2017;22(12):1506–1509. doi:10.1634/theoncologist.2017-0147.
  • Jackson I, Etuk A, Jackson N. Arrhythmia prevalence, predictors, and impact on hospital-associated outcomes among patients with diffuse large B-cell lymphoma. Am J Med Sci. 2023;365(1):56–62. doi:10.1016/j.amjms.2022.08.011.
  • Chen Z, Lu K, Zhou L, et al. Electrocardiographic characteristics of diffuse large B-cell lymphoma patients treated with anthracycline-based chemotherapy. J Electrocardiol. 2020;60:195–199. doi:10.1016/j.jelectrocard.2020.04.024.
  • Guglin M, Aljayeh M, Saiyad S, Ali R, Curtis AB. Introducing a new entity: chemotherapy-induced arrhythmia. Europace. 2009;11(12):1579–1586. doi:10.1093/europace/eup300.
  • Rawat PS, Jaiswal A, Khurana A, Bhatti JS, Navik U. Doxorubicin-induced cardiotoxicity: an update on the molecular mechanism and novel therapeutic strategies for effective management. Biomed Pharmacother. 2021;139:111708. doi:10.1016/j.biopha.2021.111708.
  • Arola OJ, Saraste A, Pulkki K, Kallajoki M, Parvinen M, Voipio-Pulkki LM. Acute doxorubicin cardiotoxicity involves cardiomyocyte apoptosis. Cancer Res. 2000;60(7):1789–1792.
  • Devi K, Shaikh MU, Ali NB, Adil SN, Khan M, Soomar SM. Outcomes of patients with double/triple expressor diffuse large B-cell lymphoma (DLBCL) treated with R-DA-EPOCH/R-CHOP: a single-center experience. Leuk Res Rep. 2021;16:100284. doi:10.1016/j.lrr.2021.100284.
  • Devitt KA, Lunde JH, Lewis MR. New onset pancytopenia in adults: a review of underlying pathologies and their associated clinical and laboratory findings. Leuk Lymphoma. 2014;55(5):1099–1105. doi:10.3109/10428194.2013.821703.
  • Alkhatib Y, Abdel Rahman Z, Kuriakose P. Clinical impact of metformin in diabetic diffuse large B-cell lymphoma patients: a case-control study. Leuk Lymphoma. 2017;58(5):1130–1134. doi:10.1080/10428194.2016.1239822.
  • Gouni S, Strati P, Toruner G, et al. Statins enhance the chemosensitivity of R-CHOP in diffuse large B-cell lymphoma. Leuk Lymphoma. 2022;63(6):1302–1313. doi:10.1080/10428194.2021.2020782.
  • Cho S-F, Yang Y-H, Liu Y-C, et al. Previous exposure to statin may reduce the risk of subsequent non-Hodgkin lymphoma: a nationwide population-based case-control study. PLoS One. 2015;10(10):e0139289. doi:10.1371/journal.pone.0139289.
  • Howlader N, Morton LM, Feuer EJ, Besson C, Engels EA. Contributions of subtypes of non-Hodgkin lymphoma to mortality trends. Cancer Epidemiol Biomarkers Prev. 2016;25(1):174–179. doi:10.1158/1055-9965.EPI-15-0921.
  • Laviana AA, Luckenbaugh AN, Resnick MJ. Trends in the cost of cancer care: beyond drugs. J Clin Oncol. 2020;38(4):316–322. doi:10.1200/JCO.19.01963.
  • Kirby A, Drummond FJ, Lawlor A, Murphy A. Counting the social, psychological, and economic costs of COVID-19 for cancer patients. Support Care Cancer. 2022;30(11):8705–8731. doi:10.1007/s00520-022-07178-0.
  • Heung Y, Zhukovsky D, Hui D, Lu Z, Andersen C, Bruera E. Quality of end-of-life care during the COVID-19 pandemic at a comprehensive cancer center. Cancers (Basel). 2023;15(8):2201. doi:10.3390/cancers15082201.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.